UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value CCEL NYSE American LLC FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 CRYO-CELL ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value CCEL NYSE American LLC Non-accelerated filer ☑ Smaller reporting company ☑ FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2024 ☐ Transition report pursuant to Section 13 or ...

SIGNATURES 54 2 CRYO-CELL INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS The accompanying notes are an integral part of these consolidated financial statements. | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------|-------------------| | | | (Unaudited) May 31, 2024 | November 30, 2023 | | ASSETS | ...

Contract modifications exist when the modification either creates new or changes in the existing enforceable rights and obligations. The Company's contracts are occasionally modified to account for changes in contract terms and conditions, which the Company refers to as an upgrade or downgrade. An upgrade occurs when a customer wants to pay for additional years of storage. A downgrade occurs when a customer originally entered into a long-term contract (such as twenty-one year or lifetime plan) but would lik ...

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023. Financial Results Revenue Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022. The revenues for fiscal 2023 consisted of $30.8 million in processing and storage fee revenue, $66,000 in product revenue and $481, ...

Title of each class Trading Symbol(s) Name of each exchange on which registered ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 Washington, D.C. 20549 (Exact Name of registrant as specified in its charter) DELAWARE 22-3023093 (State or other jurisdiction of incorporation or organi ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value CCEL NYSE American LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☑ Smaller reporting company ☑ Emerging growth company ☐ FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 Check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the regis ...

DELAWARE 22-3023093 (State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 700 Brooker Creek Blvd. Oldsmar, FL 34677 (Address of Principal Executive Offices) (Zip Code) | --- | --- | --- | --- | --- | |---------------------------------------|-------|-------------------|-------|-----------------------------------------------------| | Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered | | Common Stock, $0.01 par value | | CCEL | ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 DELAWARE 22-3023093 (State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 700 Brooke ...

On February 17, 2023, subsequent to the balance sheet date, the Company entered into a Second Amendment to the License Agreement (the "Second Amendment") with Duke. The Second Amendment changes the license fee due to Duke. The final $2,000,000 payment that was due on February 23, 2023 was removed and the license fee is paid in full. The Second Amendment added a new milestone payment of $1,000,000 upon FDA approval of the first licensed product comprising cord tissue derived MSC ("ctMSC") for autism spectrum ...